Platelet Aggregation Inhibitor
FABOLUS-FASTER
Inhibition of platelet aggregation using different regiments in patients with STEMI undergoing PCI.
Meta-analysis: Aspirin discontinuation safe soon after PCI
Dropping aspirin and continuing with P2Y12 inhibitor monotherapy 1 to 3 months after PCI was safe, according to a new meta-analysis.
Cangrelor inferior to tirofiban for platelet aggregation inhibition during PCI
Cangrelor resulted in inferior platelet aggregation inhibition compared with tirofiban in patients with STEMI who were undergoing PCI, the FABOLUS-FASTER study found.
Early intervention in NSTEACS reduces ischemic events but not CV mortality
Confirming previously presented findings, early intervention for patients who presented with non-ST-segment elevation ACS without pretreatment with P2Y12 inhibitors reduced recurrent ischemic events compared with delayed coronary angiography, but there were no differences in CV mortality.
GALILEO: Rivaroxaban raises death, thrombotic, bleeding risk vs. antiplatelet therapy after TAVR
PHILADELPHIA — Among patients who underwent successful transcatheter aortic valve replacement and were not on chronic oral anticoagulation, rivaroxaban was linked to higher risk for death/thromboembolic complications and bleeding compared with antiplatelet therapy, according to results from the GALILEO trial.
Ticagrelor monotherapy similar to DAPT regimen 2 years after stenting
Confirming previously presented results, ticagrelor monotherapy after 1 month of dual antiplatelet therapy was similar to a standard DAPT regimen for the prevention of ischemic events without differences in bleeding following drug-eluting coronary stenting.
THEMIS, TWILIGHT, other major trials spotlighted at CMHC
CHICAGO — Healio presents live updates from the late-breaking trials session at the Cardiometabolic Health Congress.
MODEL U-SES: 3-month DAPT noninferior to standard DAPT after PCI with bioresorbable SES
SAN FRANCISCO — Among patients who underwent PCI with a bioresorbable polymer sirolimus-eluting stent, 3-month dual antiplatelet therapy was noninferior to longer DAPT, according to results from the MODEL U-SES study.
IDEAL-LM: Newer EES plus shortened DAPT similar to older EES plus 1-year DAPT in left main disease
SAN FRANCISCO — Among patients with CAD in the left main artery who underwent PCI, a biodegradable polymer everolimus-eluting stent plus 4 months of dual antiplatelet therapy conferred similar outcomes as a durable polymer EES plus 1 year of DAPT, according to results from the IDEAL-LM trial.
Durable-polymer DES noninferior to polymer-free DCS in patients with high bleeding risk, shorter DAPT: Onyx ONE
SAN FRANCISCO — In the first randomized trial to compare a durable-polymer DES with a polymer-free drug-coated stent in patients with high bleeding risk who received 1 month of dual antiplatelet therapy, treatment with the DES was as safe and effective as treatment with the DCS, according to results of the Onyx ONE trial presented at TCT 2019.